Daiichi's Pexidartinib: Potential Patient Impact Drives Advisory Cmte. Recommendation
US FDA's ODAC members decide potential "life-changing" benefits of Daiichi's proposed rare cancer therapy outweigh liver risks.
You may also be interested in...
AstraZeneca and Merck seek to add a pancreatic cancer indication for olaparib, while Merck has hopes of broadening pembrolizumab’s use in bladder cancer; two-day Oncologic Drugs Advisory Committee meeting also will include reviews of Celgene’s luspatercept in myelodysplastic syndromes-related anemia and Epizyme’s tazemetostat for epithelioid sarcoma.
As the US FDA suggested during its advisory committee review, a long-term safety study is among the postmarketing commitments for the tenosynovial giant cell tumor treatment.
The latest drug development news and highlights from our US FDA Performance Tracker.